You are here

ENHANCED KIDNEY DIALYSIS MEMBRANES

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 1R43DK055910-01
Amount: $100,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1999
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
325 WATER ST
WILMINGTON, DE 19804
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 PURUSHOTTAM SHANBHAG
 () -
Business Contact
Phone: (302) 999-7996
Email: SNEMSER@COMPACTMEMBRANE.COM
Research Institution
N/A
Abstract

Not Available Conducting Materials Corp. Proposes to support the antimalarial structure-based discovery efforts at Walter Reed Army Institure of Research, Division of Experimental Therapeutics. Specifically, serine hydroxymethyltransferase, an enzyme intimately linked to the metabolic functions of dihydrofolate reductase and thymidylate syntheses, will be targeted with a new generation of antimalarial agents. In Phase I, malarial SHMT will be cloned, sequenced, and expressed in bacteria. The functional enzyme will be purified for testing against potential antimalarial agents. The catalytic activity of the enzyme will be tested against some simple variation of substrates to get an approximation of the binding preferences of the malarial SHMT. At the same time, and RNA combinatorial library (SELEX) will be established to probe at and compare the active sites of host versus parasite metabolic enzymes. For proof of principle, the RNA combinatorial system will first be applied to drug-sensitive malarial DHFR since this protein is known to bind certain antifolate 1,000 times more tightly than the host enzyme. It is expected that the SELEX system will be able to identify RNA molecules that mimic the binding properties of drugs such as pyrimethamine. Phase II will design biased combinatorial libraries of small molecules.BENEFITS:Successful outcome of phase I&II will lead to anti-malarial drug development which will overcome the problem of drug resistant malarial parasites. Such

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government